Back to results
US 5,206,140 AGranted
Assay for soluble crosslinked fibrin polymers
AssigneeResearch Corporation Technologies, Inc.
InventorsVictor J. Marder, Charles W. Francis
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeResearch Corporation Technologies, Inc.
InventorsVictor J. Marder, Charles W. Francis
Estimating the term…
This invention relates to an assay for fibrin polymers for use in the diagnosis of patients at risk of thrombosis and in monitoring the effects of treatment in such patients. More particularly, the present invention relates to an assay for soluble crosslinked fibrin polymers in patent samples involving the in vitro treatment of the sample with a proteolytic enzyme such as t-PA which generates the D-dimer fragment of soluble fibrin polymers. The amount of D-dimer formed is determined by an immunoassay specific for D-dimer. The measurement of D-dimer is thus a useful reflection of the hypercoagulability state and the test may be useful for assessing pre-thrombotic or thrombotic disorders such as myocardial infarction, pulmonary embolism and deep vein thrombosis, as well as for soluble fibrin formation in neoplastic, immune, inflammatory states, or other pathologic conditions, and for evaluations of therapy such as with anticoagulants that are used to treat these conditions.
A process for the in vitro determination of crosslinked soluble fibrin polymers in a patient sample which comprises contacting said sample with at least one proteolytic enzyme to generate the D-dimer fragment of said fibrin polymers and measuring the amount of said D-dimer.
A process for the in vitro determination of crosslinked soluble fibrin polymers in a patient sample which comprises
A diagnostic kit for assaying the amount of D-dimer in a patient sample comprising a carrier being compartmented to receive a series of containers in close confinement which comprises:
Dependencies are inferred from the claim text.